Kimelman & Baird LLC Sells 1,841 Shares of Eli Lilly and Company $LLY

Key Points

• Kimelman & Baird LLC reduced its Eli Lilly stake by 4.2% in the fourth quarter, selling 1,841 shares and leaving it with 41,878 shares worth about $45.0 million. LLY still accounts for roughly 3.5% of the firm’s portfolio and remains its 11th-largest holding.
• Institutional ownership remains very high at 82.53%, and several other large investors either added to or trimmed positions in Eli Lilly during recent quarters. This suggests continued strong interest from professional money managers despite some portfolio reshuffling.
• Analysts remain broadly constructive on LLY, with an average “Moderate Buy” rating and a consensus target price of $1,218.33. The company also recently beat quarterly earnings and revenue expectations, reinforcing confidence in its growth outlook.

Kimelman & Baird LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,878 shares of the company's stock after selling 1,841 shares during the quarter. Eli Lilly and Company makes up approximately 3.5% of Kimelman & Baird LLC's investment portfolio, making the stock its 11th largest position. Kimelman & Baird LLC's holdings in Eli Lilly and Company were worth $45,005,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in LLY. Cidel Asset Management Inc. increased its position in shares of Eli Lilly and Company by 26.5% during the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock worth $20,392,000 after buying an additional 5,591 shares during the period. Spire Wealth Management increased its position in shares of Eli Lilly and Company by 2.2% during the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company's stock worth $29,789,000 after buying an additional 592 shares during the period. Coldstream Capital Management Inc. increased its position in shares of Eli Lilly and Company by 25.6% during the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock worth $32,365,000 after buying an additional 8,659 shares during the period. Farther Finance Advisors LLC increased its position in shares of Eli Lilly and Company by 30.8% during the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company's stock worth $33,471,000 after buying an additional 7,338 shares during the period. Finally, Teachers Retirement System of The State of Kentucky increased its position in shares of Eli Lilly and Company by 3.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company's stock worth $126,022,000 after buying an additional 5,595 shares during the period. Institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Berenberg Bank increased their price objective on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a "hold" rating in a research report on Thursday, February 19th. Cantor Fitzgerald lifted their price objective on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an "overweight" rating in a research note on Friday, May 1st. CICC Research boosted their target price on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a "neutral" rating in a research report on Wednesday, February 11th. Barclays boosted their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an "overweight" rating in a research report on Monday, May 4th. Finally, UBS Group reiterated a "buy" rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and an average target price of $1,218.33.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor enthusiasm remains supported by Eli Lilly’s powerful obesity and diabetes drug franchise, with articles highlighting surging Mounjaro/Zepbound demand and expectations for continued growth. Article Title
• Positive Sentiment: Recent business momentum is still very strong, with second-quarter-level commentary pointing to major sales growth and raised revenue expectations that reinforce the company’s long-term earnings power. Article Title
• Neutral Sentiment: Eli Lilly said it will participate in Bernstein’s Strategic Decisions Conference on May 28, which could give investors updated strategic and pipeline commentary, but the event itself is not a major near-term catalyst. Article Title
• Neutral Sentiment: Healthcare stocks were broadly stronger late Monday, which may have helped support LLY alongside the sector, but this looks like a market-wide move rather than a company-specific driver. Article Title
• Negative Sentiment: The Supreme Court’s refusal to hear Lilly’s challenge keeps a Medicaid fraud verdict alive, reinforcing litigation risk and potentially raising concerns about future government-rebate disputes and legal expenses. Article Title
• Negative Sentiment: Competition in obesity treatment remains intense, with Citi data suggesting Novo Nordisk’s Wegovy pill still has a strong prescription lead over Lilly’s rival programs, which could temper near-term excitement around Lilly’s market share gains. Article Title

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $988.76 on Tuesday. The firm has a market capitalization of $931.15 billion, a PE ratio of 35.12, a price-to-earnings-growth ratio of 1.09 and a beta of 0.48. The firm has a fifty day simple moving average of $940.00 and a two-hundred day simple moving average of $999.39. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company's quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts forecast that Eli Lilly and Company will post 35.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company's payout ratio is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.